Profil bibliographique

Alexander Cheung

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

165Publications signalées

1065Citations signalées

2Affiliations récentes

Les institutions déclarées

City College of San Francisco UCSF Helen Diller Family Comprehensive Cancer Center

Les domaines associés

Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsMultiple Myeloma Research and TreatmentsBone health and treatments

Les publications récentes

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Maximum grade adverse events, regardless of attribution. AEs are summarized as n (%) for each maximum grade.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Proportion of patients who experienced any or given category of symptomatic skeletal events by the treatment arms

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Time to event (months) clinical endpoints by baseline and change in CD4+/FoxP3- (effector) proportion, CD8+ proportion, CD8+ / CD4+FoxP3- (Treg) ratio

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Supplementary File 3

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Summary of genetic findings from targeted sequencing of ctDNA and whole exome sequencing (WES) from bone biopsy specimen.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary File 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Supplementary File 1

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ proportion above vs. below median. C. baseline CD8+ / CD4+FoxP3+ (Treg) …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Radium-223 was administered as 55 kBq/kg q4weeks and pembrolizumab as 200 mg q3weeks. Biopsies were performed pre-treatment and after 8 weeks of treatment.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Immunofluorescence staining of PD-L1+ CD68 myeloid cells in the bone biopsies. A. RNAscope staining of DAPI (cyan), CD68 (orange), PD-L1 (magenta), Tim3 (green), TIGIT (white) and overlay of bone marrow metastasis. CD68+ cells that co-express PD-L1 are indicated with arrow. Tim3+ cells …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Table 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Summary of biopsy yield

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplemental Figure 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Swimmer’s plot of treatments received. Number of radium-223 and pembrolizumab doses received are listed to the left and right of the bars, respectively. The brackets “[” and “]” represent the planned break period from radium-223 dosing with “[” representing cycle 3 day …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary File 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish Dipankar Choudhury, Lucia Kwak, Alexander Cheung, Kathryn M. Allaire et autres

Supplementary File 2

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.